These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2568431)

  • 1. The in-vitro pH-dissolution dependence and in-vivo bioavailability of frusemide-PVP solid dispersions.
    Doherty C; York P
    J Pharm Pharmacol; 1989 Feb; 41(2):73-8. PubMed ID: 2568431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of polymer molecular weight on in vitro dissolution behavior and in vivo performance of celecoxib:PVP amorphous solid dispersions.
    Knopp MM; Nguyen JH; Becker C; Francke NM; Jørgensen EB; Holm P; Holm R; Mu H; Rades T; Langguth P
    Eur J Pharm Biopharm; 2016 Apr; 101():145-51. PubMed ID: 26899127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stabilisation of amorphous furosemide increases the oral drug bioavailability in rats.
    Nielsen LH; Rades T; Müllertz A
    Int J Pharm; 2015 Jul; 490(1-2):334-40. PubMed ID: 26026252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anomalous dissolution behavior of celecoxib in PVP/Isomalt solid dispersions prepared using spray drier.
    Ghanavati R; Taheri A; Homayouni A
    Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():501-511. PubMed ID: 28024614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physicochemical properties of tadalafil solid dispersions - Impact of polymer on the apparent solubility and dissolution rate of tadalafil.
    Wlodarski K; Sawicki W; Haber K; Knapik J; Wojnarowska Z; Paluch M; Lepek P; Hawelek L; Tajber L
    Eur J Pharm Biopharm; 2015 Aug; 94():106-15. PubMed ID: 25998701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique.
    Marasini N; Tran TH; Poudel BK; Cho HJ; Choi YK; Chi SC; Choi HG; Yong CS; Kim JO
    Int J Pharm; 2013 Jan; 441(1-2):424-32. PubMed ID: 23174408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation, characterization and in vitro/vivo evaluation of tectorigenin solid dispersion with improved dissolution and bioavailability.
    Shuai S; Yue S; Huang Q; Wang W; Yang J; Lan K; Ye L
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):413-22. PubMed ID: 25669445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of amorphous phase separation and crystallization on the in vitro and in vivo performance of an amorphous solid dispersion.
    Knopp MM; Wendelboe J; Holm R; Rades T
    Eur J Pharm Biopharm; 2018 Sep; 130():290-295. PubMed ID: 30064702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Copolymer Composition on In Vitro and In Vivo Performance of Celecoxib-PVP/VA Amorphous Solid Dispersions.
    Knopp MM; Nguyen JH; Mu H; Langguth P; Rades T; Holm R
    AAPS J; 2016 Mar; 18(2):416-23. PubMed ID: 26769250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and characterization of dipyridamole solid dispersions for stabilization of supersaturation: effect of precipitation inhibitors type and molecular weight.
    Vora C; Patadia R; Mittal K; Mashru R
    Pharm Dev Technol; 2016 Nov; 21(7):847-855. PubMed ID: 26333427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissolution and precipitation behavior of amorphous solid dispersions.
    Alonzo DE; Gao Y; Zhou D; Mo H; Zhang GGZ; Taylor LS
    J Pharm Sci; 2011 Aug; 100(8):3316-3331. PubMed ID: 21607951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the generation and maintenance of supersaturation during the dissolution of amorphous solid dispersions using modulated DSC and
    Baghel S; Cathcart H; O'Reilly NJ
    Int J Pharm; 2018 Jan; 536(1):414-425. PubMed ID: 29183857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
    Caron V; Tajber L; Corrigan OI; Healy AM
    Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of polymer type and drug dose on the in vitro and in vivo behavior of amorphous solid dispersions.
    Knopp MM; Chourak N; Khan F; Wendelboe J; Langguth P; Rades T; Holm R
    Eur J Pharm Biopharm; 2016 Aug; 105():106-14. PubMed ID: 27212472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probing the mechanisms of drug release from amorphous solid dispersions in medium-soluble and medium-insoluble carriers.
    Sun DD; Lee PI
    J Control Release; 2015 Aug; 211():85-93. PubMed ID: 26054795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced kinetic solubility profiles of indomethacin amorphous solid dispersions in poly(2-hydroxyethyl methacrylate) hydrogels.
    Sun DD; Ju TC; Lee PI
    Eur J Pharm Biopharm; 2012 May; 81(1):149-58. PubMed ID: 22233548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of in vitro dissolution conditions for the in vivo predictability of an amorphous solid dispersion containing a pH-sensitive carrier.
    Wendelboe J; Knopp MM; Khan F; Chourak N; Rades T; Holm R
    Int J Pharm; 2017 Oct; 531(1):324-331. PubMed ID: 28827200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the dissolution rate of poorly water soluble drug by solid dispersion and solid solution: pros and cons.
    Chokshi RJ; Zia H; Sandhu HK; Shah NH; Malick WA
    Drug Deliv; 2007 Jan; 14(1):33-45. PubMed ID: 17107929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Approach for Analyzing the Dissolution Mechanism of Solid Dispersions.
    Ji Y; Paus R; Prudic A; Lübbert C; Sadowski G
    Pharm Res; 2015 Aug; 32(8):2559-78. PubMed ID: 25715696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.